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[smooth muscle tone]{.smallcaps} in resistance arteries and arterioles is an important determinant of peripheral vascular resistance and blood pressure ([@r29]). By controlling membrane potential and the level of free intracellular Ca^2+^ available to the contractile apparatus, voltage-activated K^+^ channels (K~v~) are crucial in regulating arterial smooth muscle tone ([@r38]). Based on electrophysiological studies, two major K~v~ current components have been identified in vascular smooth muscle cells; namely, the delayed rectifier K^+^ current and the transient A-type K^+^ current. However, this broad classification fails to reveal the highly diverse nature of the K~v~ channels that underlie these currents, and in fact, a host of delayed rectifier and A-type K^+^ currents have been reported in arterial smooth muscle with distinct biophysical and pharmacological properties ([@r9]). This diversity stems in part from the large number of gene families that encode the pore-forming K~v~α subunits (K~v~1--11) but also from other processes such as alternative splicing, heterotetrameric assembly of members within the same K~v~α subfamily, and interaction of the channels with accessory subunits ([@r8]). Despite this complexity, recent efforts have been directed toward identifying the molecular composition of the K~v~ channels that underlie functional K~v~ currents in arterial smooth muscle, and evidence has begun to emerge suggesting that some delayed rectifier currents may arise as a consequence of heterotetrameric assembly of distinct K~v~1α subunits ([@r2], [@r4]--[@r7], [@r15], [@r22], [@r26], [@r27], [@r31], [@r39]). The molecular composition of A-type currents in myocytes of the systemic circulation is not clear at this time ([@r9]); however, K~v~3.4 and K~v~4 channels appear to be the most likely determinants of these currents in pulmonary arterial smooth muscle ([@r20]).

K^+^ channel α-subunits with A-type properties are found in several K~v~ channel subfamilies, including Shaker (K~v~1.3, K~v~1.4, and K~v~1.7), Shaw (K~v~3.3 and K~v~3.4), and Shal (K~v~4.1, K~v~4.2, and K~v~4.3), and transcripts for all of these subunits have been detected in vascular smooth muscle ([@r9]). In addition, co-expression of K~v~β1 or Kβ3 accessory subunits with certain K~v~1α subunits confers rapid inactivation on otherwise noninactivating delayed rectifier channels ([@r18], [@r25], [@r33]). K~v~β subunit expression has been identified in several types of arterial smooth muscle ([@r9]). Rapid inactivation of A-type K~v~ channels is thought to be conferred by "ball" domains in the NH~2~ termini of the relevant K~v~α subunits and K~v~β1 and K~v~β3 subunits (N-type inactivation) ([@r32]). Upon depolarization, these domains occlude the channel pore by binding to a receptor near or at the cytoplasmic side of the pore ([@r21]).

We have recently described a rapidly inactivating A-type current in retinal arteriolar smooth muscle cells, which appears to play a physiological role in suppressing cell excitability and contractility ([@r28]). In the present study we have used this preparation as a model system to begin to resolve the molecular nature of the A-type current in myocytes of the peripheral systemic circulation. By combining a range of pharmacological, molecular, immunohistochemical, and neutralizing antibody approaches, we show that K~v~1.5, most likely co-assembled with K~v~β1, comprises a principal component underlying the A-type K^+^ current in this tissue.

MATERIALS AND METHODS
=====================

Retinal arteriole preparation.
------------------------------

Male Sprague-Dawley rats (200--300 g) were anesthetized with CO~2~ and killed by cervical dislocation. Retinas were rapidly removed, and arterioles, devoid of surrounding neuropile, were isolated as previously described ([@r37]). In brief, retinas were lightly triturated using a fire-polished Pasteur pipette (internal tip diameter 0.3 mm) in a low Ca^2+^ Hanks\' solution. The resulting homogenates were centrifuged at 2,800 rpm (952 *g*) for 1 min, the supernatant was aspirated off, and the tissue was washed again with low Ca^2+^ medium. The suspension was then stored at 21°C until needed. Arteriolar segments remained useable for up to 10 h under these conditions.

Patch-clamp recording.
----------------------

Voltage-clamp experiments were performed using the whole cell-perforated patch-clamp technique as previously described ([@r28]). One milliliter of homogenate was pipetted into a rectangular glass-bottomed recording bath on the stage of an inverted microscope (Nikon Eclipse, TE2000). Arterioles were anchored down with tungsten wire slips (50 μm diameter, 2 mm length) and continuously superfused with normal Hanks\' solution at 37°C to remove extraneous retinal tissue from the bathing medium. Before the electrophysiological recording, vessels were digested for 20-min with an enzyme cocktail of collagenase 1A (0.1 mg/ml) and protease type XIV (0.01 mg/ml) to remove surface basal lamina. Enzyme and drug solutions were delivered via a seven-way micromanifold with an exchange time of 1 s as measured by switching over to dye solution. The flow from the manifold into the bath was through a single tube (350 μm in diameter, 6 mm in length, 0.2-μl volume) long enough to allow the temperature to equilibrate with the solution flowing through the bath. Gigaseals were formed directly on arteriolar smooth muscle cells still embedded within their native arterioles. Electrodes (1--2 MΩ in free bathing solution) were pulled from filamented borosilicate glass capillaries (1.5 mm od w 1.17 mm id, Clark Electromedical Instruments, UK), and the patch-clamp amplifier used was an Axopatch-1D (Axon Instruments, Foster City, CA). The pipette solution was K^+^ based with amphotericin B as the perforating agent (see *Drugs and solutions*). Contaminating currents through Ca^2+^-activated K^+^ and Cl^−^ channels were minimized in all experiments by including 100 nM Penitrem A and 1 mM 9-anthracene carboxylic acid in the external bathing medium. Recordings were delayed until full perforation of the membrane patch had been achieved, as judged from the development of repeatable currents in response to step depolarizations: this usually took 3--5 min. Recordings were low pass filtered at 0.5 kHz and sampled at 2 kHz by a National Instruments PC1200 interface using software provided by John Dempster (University of Strathclyde, UK). Leakage currents were subtracted off-line from the active currents with the use of the standard leak subtraction protocol contained within the Patch software suite. Liquid junction potentials (\<2 mV) were compensated electronically. Series resistance (∼30 MΩ) was routinely compensated by \>70%. For determination of whole cell current densities, cell membrane capacitance was determined from the time constant of a capacitance transient elicited by a 20-mV depolarization from −80 mV with a sampling frequency of 20 kHz.

To evaluate the effects of pharmacological agents, outward A-type K^+^ current was first elicited by voltage steps from −80 mV to +20 mV (500 ms, 10-s intervals) in drug-free medium and then in bath solution containing the drug of interest. We have previously shown that the A-type K^+^ current in retinal arteriolar smooth muscle is closely approximated by the peak minus the sustained components of the net outward current in Penitrem A and 9-anthracene carboxylic acid ([@r28]). With the use of this method to isolate the A-type K^+^ current, the peak current densities for each vessel was averaged from five voltage steps before and then after drug application, and changes were expressed as a percentage for a minimum of four vessels per treatment group. For experiments using antibodies, conventional whole cell recordings were performed. Pipettes were dipped in an antibody-free intracellular solution and then back filled with the pipette solution containing the antibody of interest \[anti-K~v~1.4~(589--655)~ or anti-K~v~1.5~(513--602)~; Alomone Labs, Jerusalem, Israel\]. Aliquoted antibodies were defrosted daily to avoid degradation. Because the antibody experiments did not permit pairwise comparisons to be made within the same vessel, to improve resolution of changes across treatment groups, voltage steps were applied from −80 mV to +80 mV, where average peak current densities in control vessels are twice those observed at +20 mV.

Characterization of patch-clamp preparation.
--------------------------------------------

Each rat retina yielded approximately two to three first-order arterioles (35--50 μm diameter, 50--500 μm in length). The arterioles were uncontracted and easily distinguished from venules by their thick wall of circularly arranged smooth muscle cells ([Fig. 1](#f1){ref-type="fig"}). As noted above, just before the patch-clamp recording, vessels were anchored down in the recording bath and digested for 20 min with an enzyme cocktail of collagenase and protease. In addition to removing the basal lamina to facilitate gigaseal formation, this treatment electrically uncouples the endothelial cells from the overlying arteriolar smooth muscle ([@r28]). In other types of arterioles, the smooth muscle cells are also known to be electrically coupled via gap junctions ([@r10], [@r19], [@r41], [@r42]). In our earlier work, we did not investigate whether the retinal arteriolar smooth muscle layer remains electrically coupled following enzyme treatment. An indirect method to evaluate this is to compare cell capacitance measurements with the estimated cell surface area for a single arteriolar myocyte. In the present study, cell capacitance was measured as 13.1 ± 0.48 pF (*n* = 31), indicating a total patch-clamped membrane surface area of ∼1,310 μm^2^. The dimensions of individual retinal arteriolar myocytes from first-order arterioles were estimated by confocal scanning laser microscopy in vessels loaded for 10 min with the membrane-tracking dye di-4-ANEPPs (10 μM) ([@r11]); average dimensions for length (based on the vessel circumference), width, and height were 121.3, 5.7, and 2 μm, respectively (21 cells; *n* = 4 vessels). When we used these values and assumed a scalene ellipsoid structure, the approximate surface area for a single retinal arteriolar myocyte was calculated according to the Knud Thomsen formula: $$\documentclass[10pt]{article}
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The approximated cell surface area using this method was calculated to be 1,220 μm^2^, suggesting our electrophysiological recordings are most likely confined to individual myocytes. To further verify this, experiments were undertaken using the gap junction inhibitor 18β-glycyrrhetinic acid (18β-GA). In mesenteric arterioles, 40 μM 18β-GA causes a rapid block of electrical communication within the smooth muscle layer, as denoted by a switch from predominantly slow to fast capacitative transients ([@r41]). In the present study, no changes in the capacitative currents were observed in enzyme-digested arterioles exposed to 100 μM 18β-GA (capacitances were 12.53 ± 0.81 pF and 11.86 ± 0.97 pF, before and after 18β-GA, respectively; *n* = 9; *P* = 0.18). Taken together, the above results strongly suggest that following collagenase and protease treatment retinal arteriolar smooth muscle cells within intact vessel segments are electrically uncoupled from their neighboring cells.

PCR gene amplification.
-----------------------

Retinal homogenates were placed in a 2-ml recording chamber on the stage of an inverted microscope and between 5 and 13 vessels collected for each PCR experiment using single tungsten wire slips (50 μm in diameter, 5 mm length). Total RNA was extracted using RNeasy minikit (Qiagen, Crawley, UK) according to the manufacturer\'s protocol. Total RNA was also extracted from brain pia. Samples were split into two aliquots, and first-strand cDNA was prepared from one aliquot using Sensiscript Reverse Transcription kit (Qiagen). The other aliquot was used in an equivalent reaction lacking enzyme to control for potential genomic or extraneous DNA contamination \[no reverse transcriptase (RT)\]. The cDNA RT products were amplified with K~v~1.4-, K~v~1.5-, K~v~β1-, and K~v~β3-specific primers by RT-PCR using Qiagen HotStar Taq reagents. The primer pairs, relevant Genbank entries, and expected product sizes are listed in [Table 1](#t1){ref-type="table"}. All products were resolved on 2.5% agarose gels and visualized by ethidium bromide fluorescence.

Immunohistochemistry.
---------------------

For immunofluorescence experiments, retinal arterioles were visualized while embedded within retinal flatmount preparations. The advantage of this technique over the use of isolated arterioles is that negative results within the vasculature can be cross-referenced with other cell types in the retina to gauge the degree of antibody reactivity. Freshly enucleated eyes were placed in low Ca^2+^ Hanks\' solution, and the anterior segment lens complexes were removed. The posterior eye cup was fixed in 4% paraformaldehyde for 20 min and washed extensively in phosphate-buffered saline (PBS) throughout a 4-h period. Retinas were subsequently detached and soaked in PBS containing 0.5% Triton X-100 to permeabilize the tissue and 5% normal donkey serum (Chemicon International, Temecula, CA) to block nonspecific binding of the primary antibody. K~v~1.4, K~v~1.5, and K~v~β1 were detected in separate experiments using rabbit polyclonal antibodies targeted to rat, mouse, and human sequences, respectively \[anti-K~v~1.4~(589--655)~ and anti-K~v~1.5~(513--602)~; Alomone Labs, Jerusalem, Israel; anti-K~v~β1~(311--360)~; abcam, Cambridge, UK\]. Tissue was incubated in primary antibody at a dilution of 1:100 (anti-K~v~1.4 and anti-K~v~1.5) or 1:200 (anti-K~v~β1) in the permeabilization buffer overnight at 4°C and then extensively washed for 4 h at 21°C. A 1:200 dilution of a donkey anti-rabbit IgG labeled with Alexa-488 (Molecular Probes Europe BV, Leiden, The Netherlands) was used for secondary detection; the staining time and subsequent washing were the same as that used for the primary antibody. The specificity of the antibodies was investigated by parallel control experiments in the absence of primary antibody. To facilitate rapid identification of arterioles within the retinal neuropile, propidium iodide nuclear stain was used. Retinas were incubated in 5 nmol/l of propidium iodide (Invitrogen, Carlsbad, CA) in PBS for 30 min at 37°C. Retinas were flattened by placing four radial cuts from the retinal periphery to points within 1 mm from the optic disk and mounted in Vectashield (Vector Laboratories, Burlingame, CA). Images were acquired using an Olympus BX60 fluorescence microscope (Olympus, London, UK) fitted with a MicroRadiance confocal-scanning laser microscope (Bio-Rad).

Drugs and solutions.
--------------------

Hanks\' solution contained (in mM) 140 NaCl, 5 KCl, 5 [d]{.smallcaps}-glucose, 2 CaCl~2~, 1.3 MgCl~2~, 10 HEPES; pH 7.4 with NaOH. Low Ca^2+^ medium differed only in that it contained 0.1 mM CaCl~2~. K^+^-free medium was the same as normal Hanks\' solution without 5 mM KCl. For patch-clamp recordings the pipette solution contained (in mM) 138 KCl, 1 MgCl~2~, 0.5 EGTA, 10 HEPES (pH adjusted to 7.2 using NaOH) to which 300 μg/ml amphotericin B was added in perforated patch mode.

Amphotericin B, collagenase 1A, penitrem A, protease type XIV, 9-anthracene carboxylic acid, 18β-glycyrrhetinic acid, flecainide, and riluzole were purchased from Sigma-Aldrich (Poole, UK). Correolide was a kind gift from Dr. Maria Garcia and Dr. Jianming Bao of Merck Research Laboratories, Rahway, NJ. Phrixotoxin-2, rHeteropodatoxin-2, rHongotoxin-1, rNoxiustoxin, and BDS-I were obtained from Alomone Labs.

Data analysis.
--------------

Data are reported as means ± SE; *n* refers to the number of vessels tested. Significant differences between control and experimental treatments were determined using the paired *t*-test. Antibody experiments were analyzed using one-way ANOVA. *P* values \<0.05 were considered significant.

RESULTS
=======

Pharmacology of the A-type K^+^ current in retinal arteriolar smooth muscle.
----------------------------------------------------------------------------

Over recent years there has been a substantial increase in the number of toxins available that inhibit K~v~ channels. Taking impetus from this, we tested a range of pharmacological blockers as a first step in resolving likely K~v~ channel components underlying the A-type K^+^ current in retinal arteriolar myocytes. Initially, we screened agents that selectively block A-type K~v~α subunits within the main K~v~ channel subfamilies. Cells were held at −80 mV, and command voltage steps to +20 mV were applied. Phrixotoxin-2 and heteropodatoxin-2 are peptides from spider venoms that specifically inhibit K~v~4 channels ([@r12], [@r36]). Neither of these toxins applied at concentrations higher than reported IC~50~ values affected the A-type K^+^ current in retinal arteriolar myocytes nor did BDS-I, a K~v~3.4 channel antagonist ([@r13]) (see [Fig. 2](#f2){ref-type="fig"} and [Table 2](#t2){ref-type="table"}). Correolide is a novel nortriterpine from the Costa Rican tree *Spachea correa* that selectively binds to and blocks members of the K~v~1 channel subfamily ([@r14], [@r17]). In four retinal arterioles, 10 μM correolide inhibited the peak A-type K^+^ current by \>70% ([Fig. 2](#f2){ref-type="fig"} and [Table 2](#t2){ref-type="table"}). In accord with its slow-onset kinetics ([@r14]), and consistent with previous reports in cerebral arteriolar myocytes ([@r2]), the blocking effects of correolide on the K~v~ current developed slowly taking 5--10 min to reach maximal levels.

The above data support the idea that Kv1 channels may underlie the A-type K^+^ current in retinal arteriolar myocytes. The K~v~1 channel subfamily consists of multiple members (K~v~1.1--1.7), and several K~v~1α subunits are known to display A-type properties, including K~v~1.3, K~v~1.4, and K~v~1.7 ([@r3]). Moreover, the accessory subunit K~v~β1.1 can induce rapid inactivation of delayed rectifier type K~v~1 channels, including K~v~1.1, K~v~1.2, and K~v~1.5, but not K~v~1.6 ([@r18]). Since most K~v~1 channels could potentially represent molecular candidates of the A-type K^+^ current in retinal arteriolar myocytes, we extended our pharmacological approach using known inhibitors that specifically target various members of this subfamily. Hongotoxin is a peptide from venom of the scorpion *Centruroides limbatus*, which is known to block homotetrameric K~v~1.1, K~v~1.2, and K~v~1.3 channels (IC~50~s in 31--170 pM range) and also K~v~1.6 with low affinity (IC~50~ = 6 nM) ([@r23]). In retinal arteriolar smooth muscle, 100 nM recombinant hongotoxin did not suppress the A-type K^+^ current ([Fig. 3](#f3){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). To further eliminate a possible contribution by Kv1.2--1.3 homotetramers, we tested the effects of noxiustoxin, another scorpion-derived toxin that binds to and blocks these channels at low concentrations (IC~50~ values of 1 and 2 nM, respectively) ([@r16]). K~v~1.7 is also potently blocked by noxiustoxin at nanomolar levels (IC~50~ of 18 nM) ([@r8]). Recombinant noxiustoxin (20 nM) had no effect on the A-type K^+^ current in retinal arterioles ([Fig. 3](#f3){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). Riluzole is a neuroprotective drug that modulates K~v~1.4 channels via the oxidation of a cysteine residue in the NH~2~-terminal inactivation ball (IC~50~ of 70 μM) ([@r40]). More recently, it has also been shown that this drug inhibits cloned K~v~1.5 channels by preferentially binding to the inactivated and to the closed states of the channel (IC~50~ 40 μM) ([@r1]). Riluzole (100 μM) inhibited the A-type K^+^ current by 32 ± 7% at +20 mV ([Fig. 3](#f3){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). To begin to isolate the possible contributions of K~v~1.4 and K~v~1.5 channels to the A-type K^+^ current, we investigated the effects of K^+^-free bathing medium and the anti-arrhythmic agent flecainide ([Fig. 3](#f3){ref-type="fig"}, [Table 3](#t3){ref-type="table"}). Removal of extracellular K^+^ is known to suppress current through K~v~1.4 channels but not K~v~1.5 ([@r30]), and in retinal arteriolar myocytes, exposure to K^+^-free medium elicited no change in the peak A-type K^+^ current. Classically, flecainide has been used to discriminate Kv4-based A-type K^+^ currents (flecainide sensitive; IC~50~ ∼ 10 μM) from those mediated by Kv1.4 channels (flecainide insensitive; IC~50~ = 700 μM) ([@r43]). Similar to K~v~4 channels, K~v~1.5 is also known to be sensitive to flecainide at low micromolar concentrations ([@r16]), and application of 20 μM flecainide inhibited the A-type K^+^ current in retinal arterioles by \>80%.

Expression and neutralizing antibody studies further confirm a role for K~v~1.5.
--------------------------------------------------------------------------------

Our pharmacological data suggest that the A-type K^+^ current in retinal arteriolar myocytes is mediated, at least in part, by K~v~1.5-containing channels. To provide further evidence that K~v~1.5 underlies the A-type K^+^ current, RT-PCR was initially used to screen for mRNAs encoding K~v~1.4 and K~v~1.5 in freshly isolated retinal arterioles. RNA samples were collected from 5 to 13 arterioles, and rat brain pial membrane was used as a positive control ([@r6]). K~v~1.5 mRNA was consistently detected in retinal arterioles but K~v~1.4 was not evident ([Fig. 4*A*](#f4){ref-type="fig"}). Lack of K~v~1.4 expression could not be attributed to primer design, since K~v~1.4 transcript expression was verified in the brain using the same primer pairs. No products were detected in any of the minus-reverse transcriptase control experiments (no amplification controls). Immunofluorescence staining with commercially available polyclonal antibodies was also used to test for cell-specific expression of K~v~1.4 and K~v~1.5 in retinal arterioles embedded within retinal flatmount preparations. To ensure that the images collected originated from the arterioles, the retinas were counterstained with propidium iodide nuclear stain. First-order arterioles radiating from the optic disk were readily identified by their distinctive monolayer of smooth muscle cell nuclei (see, for example, [Fig. 4*B*](#f4){ref-type="fig"},*i*), which was absent on interdigitating venules. Endothelial cell nuclei could also be seen just below the focal plane of the arteriolar smooth muscle cells and orientated in a longitudinal direction ([Fig. 4*B*](#f4){ref-type="fig"},*i*). Consistent with the RT-PCR results, K~v~1.4 could not be detected in retinal arterioles ([Fig. 4*B*](#f4){ref-type="fig"}, *i* and *ii*). This was not due to a lack of antibody reactivity because intense staining was observed in the outer nuclear layer of the retina ([Fig. 4*B*](#f4){ref-type="fig"}, *iii* and *iv*), which was not apparent in flatmounts exposed to only secondary antibodies (2°Control; [Fig. 4*B*](#f4){ref-type="fig"},*v*). In contrast to K~v~1.4, strong immunoreactivity was detected for K~v~1.5 in retinal arterioles localized to the plasma membrane of the arteriolar smooth muscle cells ([Fig. 4*B*](#f4){ref-type="fig"}, *vi* and *vii*). Anti-K~v~1.5 staining was not visible in endothelial cells (data not shown), and 2°Controls were negative ([Fig. 4*B*](#f4){ref-type="fig"}, *viii* and *ix*).

Recently, neutralizing antibody approaches have been successfully used to demonstrate the contribution of specific K~v~α subunits to observed macroscopic K~v~ currents in native vascular smooth muscle cells ([@r44]). Conventional whole cell recordings were used to dialyze anti-K~v~1.4 and anti-K~v~1.5 antibodies into the cytosol of individual retinal arteriolar myocytes. The anti-K~v~1.5 antibody employed has previously been demonstrated to specifically block K~v~1.5 currents when applied intracellularly to mesenteric artery smooth muscle cells ([@r26]). Since gene and protein expression for K~v~1.4 could not be detected in retinal arterioles, anti-K~v~1.4 antibody was chosen as a negative control. Without antibody in the pipette, the A-type current was stable for periods \>20 min. In the presence of anti-K~v~1.5 antibody in the pipette solution, the A-type current was inhibited within 2--5 min after establishment of the whole cell configuration by 64 ± 11% ([Fig. 5](#f5){ref-type="fig"}). Application of anti-K~v~1.4 antibody in the pipette solution did not have any effect on the A-type current even after 20 min of recording ([Fig. 5](#f5){ref-type="fig"}). Anti-K~v~1.5 antibody also inhibited the sustained component of the net outward current ([Fig. 5*A*](#f5){ref-type="fig"}; current densities were 44.1, 52.2, and 22.3 pA/pF for controls, anti-K~v~1.4 antibody, and anti-K~v~1.5 antibody, respectively; *P* \< 0.05 for anti-K~v~1.5 vs. other groups), suggesting that some of the delayed rectifier channels in this tissue may also contain K~v~1.5 subunits.

Contribution of K~v~β1 to the A-type K^+^ current.
--------------------------------------------------

The above results strongly suggest that K~v~1.5 constitutes a principal molecular component underlying the A-type current in retinal arteriolar smooth muscle. In heterologous expression systems, K~v~1.5 classically gives rise to delayed rectifier, not A-type currents. However, co-expression of K~v~1.5 with K~v~β1 or K~v~β3 accessory subunits can transform the current into a rapidly inactivating A-type current ([@r18], [@r25]). To examine whether this mechanism might be of relevance in retinal arteriolar myocytes, we initially sought evidence for mRNA transcript expression of K~v~β1 and K~v~β3 subunits in freshly isolated retinal arterioles. K~v~β1 product was consistently detected; however, no definite expression of K~v~β3 mRNA was observed ([Fig. 6*A*](#f6){ref-type="fig"}). K~v~β3 was detected in rat brain pial membrane ([Fig. 6*A*](#f6){ref-type="fig"}). K~v~β1 protein expression in retinal arterioles was confirmed by immunohistochemistry of retinal flatmount preparations ([Fig. 6*B*](#f6){ref-type="fig"}). At low magnifications, K~v~β1-associated fluorescence was most intense in retinal astrocytes, particularly in the end feet surrounding blood vessels ([Fig. 6*B*](#f6){ref-type="fig"},*i*). At higher magnifications, K~v~β1 was also observed to be specifically localized to the plasma membrane of retinal arteriolar myocytes ([Fig. 6*B*](#f6){ref-type="fig"}, *ii* and *iii*), but was absent in the endothelial cell layer ([Fig. 6*B*](#f6){ref-type="fig"},*iv*).

DISCUSSION
==========

This study is the first to examine the molecular composition of the K~v~ channels underlying the A-type K^+^ current in vascular smooth muscle cells of the peripheral systemic circulation. Similar studies have previously been undertaken to identify the molecular nature of the K~v~ channels underlying delayed rectifier currents in arterial myocytes. The general consensus from these studies is that slowly inactivating tetraethylammonium (TEA)-insensitive delayed rectifier currents arise through heterotetrameric complexes of K~v~1.2 with K~v~1.4 or K~v~1.5 channels associated with a K~v~β1 subunit, whereas TEA-sensitive delayed rectifier currents most likely contain at minimum K~v~2.1 α-subunits ([@r9]). From the present study it appears that the molecular identity of the A-type K^+^ current in retinal arteriolar smooth muscle closely resembles the TEA-insensitive delayed rectifier current observed in other types of arterial smooth muscle in that K~v~1.5 appears to be a major component and is probably co-assembled with K~v~β1 subunits.

Previous studies concerned with the molecular composition of K~v~ channels in arterial smooth muscle have begun by systematically screening K~v~ channel gene expression. Although this approach represents a logical starting point for identifying potential candidate α-subunits, data interpretation is often confounded by the multitude of K~v~ channel isoforms expressed when compared with the number of K~v~ current components observed ([@r9]). For this reason we initially adopted a pharmacological strategy to narrow down likely K~v~ channel components underlying the A-type K^+^ current. This type of approach has only recently become feasible with the emergence of an increasing number of drugs and toxins that selectively target specific members of the K~v~ channel superfamily. A caveat to this kind of approach, however, is that some of the drugs and toxins are only active against homotetrameric K~v~ channels ([@r35]), and hence, a lack of effect does not necessarily exclude the possibility that the subunit(s) of interest forms part of heterotetrameric K~v~ complex. Thus, although we can confidently exclude K~v~1.1/2/3/4/6 and 7 homotetrameric channels as contributing to the A-type K^+^ current in retinal arteriolar smooth muscle, these subunits could still play a crucial role in the observed currents by forming heterotetrameric complexes with K~v~1.5. In fact, we have previously shown that the A-type K^+^ current in retinal arterioles is partially suppressed by low levels of TEA (10 mM) ([@r28]), yet it is established that K~v~1.5 homotetrameric channels are resistant to the actions TEA ([@r16]). This strongly suggests that the channels underlying the A-type K^+^ current in retinal arteriolar smooth muscle cells are heterotetrameric complexes of K~v~1.5 with TEA-sensitive K~v~1α subunits such as K~v~1.1 and K~v~1.6 ([@r8], [@r16]).

A distinctive feature of A-type K^+^ currents bestowed by K~v~1.5 channels assembled with K~v~β1 subunits is the voltage for half-inactivation, which at −31.5 mV ([@r18]) is around 20--30 mV more positive than A-type K^+^ currents mediated by the majority of α-subunits in other K~v~ subfamilies ([@r8]). We have previously reported a half-inactivation voltage for the A-type K^+^ current in the retinal arteriolar smooth muscle of −28.3 mV ([@r28]), and this adds further weight to the notion that K~v~1.5-containing channels co-assembled with K~v~β1 subunits form the basis of this current. There is, nonetheless, a discrepancy in the relation to the time constant for recovery from inactivation. A-type K^+^ currents mediated by the K~v~1 family of channels recover relatively slowly from inactivation ([@r3]), and for K~v~1.5/K~v~β1 channels, the time constant is 2.4 s ([@r18]). The time constant for recovery from inactivation of the A-type K^+^ current in retinal arteriolar myocytes is 118 ms ([@r28]), which is more reminiscent of K~v~4-derived currents. Few studies have specifically addressed those factors involved in modulating recovery from inactivation for K~v~1 channels, although it is notable that Ca^2+^/calmodulin-dependent kinase (CAMKII) phosphorylation of an NH~2~ terminal residue of K~v~1.4 leads to an accelerated recovery from N-type inactivated states ([@r34]). Retinal arteriolar smooth muscle cells exhibit a very high level of spontaneous subcellular Ca^2+^ signaling activity ([@r11]), and this would be consistent with the idea that CAMKII-dependent regulation of K~v~1.5/K~v~β1 may be more relevant in this tissue than in heterologous expression systems where the biophysical properties these channels have been previously determined. Although it remains unclear if the phosphorylation status of Kvβ subunits modifies recovery from N-type inactivation of K~v~1 channels, protein kinase A phosphorylation of serine-24 in the NH~2~ terminus of K~v~β1.3 is known to alter the kinetics of inactivation of K~v~1.5 ([@r24]).

By using a multi-faceted approach, we have identified K~v~1.5 as being a principal component underlying the A-type K^+^ current in retinal arteriolar smooth muscle cells. It seems likely that K~v~1.5 forms a heterotetrameric complex with other TEA-sensitive K~v~1α subunits and that the transient nature of the current arises through association of the channels with K~v~β1 subunits. Intriguingly, the molecular components underlying the A-type K^+^ current in retinal arterioles appear similar to those that mediate delayed rectifier K^+^ currents in other types of vascular smooth muscle. Although the physiological significance of these observations warrants further investigation, it is evident that we should not necessarily consider A-type and delayed rectifier K^+^ currents in vascular smooth muscle as separate K~v~ current components. Instead, these currents may be derived from K~v~ channels with similar α-subunit compositions but reflect opposing ends of a spectrum of kinetically distinct currents that vary according to their degree of regulation by K~v~β subunits.
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![Photomicrographs of a freshly isolated rat retinal arteriole and venule. Scale Bars, 10 μm.](zh40020772410001){#f1}

![Typical records showing the effects of selective A-type K~v~α subfamily inhibitors on the A-type K^+^ current in retinal arteriolar smooth muscle cells. K~v~ currents were elicited by voltage steps from −80 to +20 mV before and during application of the relevant antagonist. Arterioles were in the continuous presence of 100 nM Penitrem A and 1 mM 9-anthracene carboxylic acid (9-AC) to prevent contamination by Ca^2+^-activated K^+^ and Cl^−^ currents, respectively. No effects on the peak A-type K^+^ current were observed with the K~v~4 channel blockers heteropodatoxin-2 (*A*) and phrixotoxin-2 (*B*) or the K~v~3.4 antagonist BDS-I (*C*). In contrast, the A-type K^+^ current was blocked by 10 μM correolide (*D*), a selective inhibitor of K~v~1 channels. Average data for these experiments are presented in [Table 2](#t2){ref-type="table"}.](zh40020772410002){#f2}

![Electrophysiological traces showing the effects of K~v~1 channel modulators on the A-type K^+^ current in retinal arteriolar smooth muscle cells. Whole cell currents were evoked by voltage steps from −80 to +20 mV. Hongotoxin (*A*) and noxiustoxin (*B*), which collectively inhibit K~v~1.1/2/3/6 and 7 homotetrameric channels, did not affect the A-type K^+^ current, whereas some reduction was observed in the presence of 100 μM riluzole (*C*), a known blocker of K~v~1.4 and K~v~1.5 channels. No effects were seen following removal of extracellular K^+^ (0K~o~; *D*), but the current was almost completely abolished by 20 μM flecainide (*E*). Mean data for these protocols are summarized in [Table 3](#t3){ref-type="table"}.](zh40020772410003){#f3}

![Screening by RT-PCR and immunofluorescence for K~v~1.4 and K~v~1.5 expression in rat retinal arterioles. *A*: 167-bp product of K~v~1.5 was detected by RT-PCR in freshly isolated retinal arterioles, but K~v~1.4 transcript expression was not observed. Rat brain pial membrane was used as a positive control and minus lanes represent no RT controls. Detection of K~v~1.5 and not K~v~1.4 was verified in cDNA reverse transcribed from three different RNA isolations. *B*: cellular localization of K~v~1.4 and K~v~1.5 in arterioles embedded within retinal flatmount preparations. All red images are propidium iodide (PI) nuclear stain. Arteriole was stained with PI (*i*) and anti-K~v~1.4 (*ii*); no immunoreactivity for anti-K~v~1.4 was detected. VSM refers to vascular smooth muscle. Outer Nuclear Layer (ONL) of retina was stained with PI (*iii*) and anti-K~v~1.4 (*iv*). Control staining in the absence of primary antibody in the ONL (*v*) is shown. PI (*vi*) and anti-K~v~1.5 (*vii*) staining in an arteriole with surrounding retinal ganglion cells are shown. Control staining for a PI-labeled retinal arteriole (*viii*) without primary antibody (*ix*) are shown. Scale bars, 10 μm](zh40020772410004){#f4}

![Effects of anti-K~v~1.4 and anti-K~v~1.5 antibodies on the A-type K^+^ current in retinal arteriolar smooth muscle. *A*: whole cell K^+^ currents elicited by voltage steps from −80 to +80 mV in the absence and presence of either anti-K~v~1.4 or anti-K~v~1.5 antibody in the pipette solution. Records were obtained 5 min after establishment of the whole cell configuration. *B*: summary of effects of the antibodies on peak current density for the A-type current. Six vessels were tested per treatment group. \*\**P* \< 0.01.](zh40020772410005){#f5}

![*A*: K~v~β transcript expression in freshly isolated rat retinal arterioles. Expression of K~v~β1 transcript, but not K~v~β3, was evident. Brain was used as a positive control and minus lanes represent no RT controls. *B*, *i*: low magnification confocal image of a retinal flatmount preparation stained with PI (red) and anti-Kvβ1 (green) focused at the level of the ganglion cell layer. Strong Kvβ1-associated immunofluorescence was seen in the retinal astrocytes. Scale bar, 50 μm. Higher magnification image of retinal arteriole stained with PI (*ii*) and anti-K~v~β1 (*iii*). *iv*: luminal confocal image of a retinal arteriole showing that Kvβ1-associated immunofluorescence was limited to the arteriolar smooth muscle cells. Scale bars for *B, ii--iv*, 10 μm.](zh40020772410006){#f6}

###### 

Genbank entries, primer sequences, and expected product sizes

  MRNA (Accession No.)             Primer Sets                         Expected Size, BP
  -------------------------------- ----------------------------------- -------------------
  K~v~1.4 ([NM012971](NM012971))   For. `GGAAATTAACTTTTGAAAAGGCTGCT`   216
                                   Rev.` TTGGTGCGTTAGTAAACATTCACAG`    
  K~v~1.5 ([NM012972](NM012972))   For. `TGAAGGAAGAACAAGGCAACCA`       167
                                   Rev. `GGCCTTGAGGTGACACTTTTCTAGA`    
  K~v~β1 ([NM017303](NM017303))    For. `GCACACTACCTCAGCTGGCTGT`       176
                                   Rev. `GGGCTTGTTGCGCAATATGT`         
  K~v~β3 ([NM031652](NM031652))    For. `CACAAAATTGGTGTTGGCTCAGT`      134
                                   Rev. `TGCACTTTTTCTTTGAGCCACTG`      

###### 

Mean data showing the effects of specific Kv subfamily inhibitors on the A-type K^+^ current in retinal arteriolar myocytes

  Inhibitor           K~v~α Subunits Inhibited   Mean Block±SEM, %                             *P* Value (No. of Vessels)
  ------------------- -------------------------- --------------------------------------------- ----------------------------
  Heteropodatoxin 2   K~v~ 4.2                   −4.77±7.28[\*](#t2fn1){ref-type="table-fn"}   NS (4)
  Phrixotoxin 2       K~v~ 4.2, 4.3              −0.54±1.97[\*](#t2fn1){ref-type="table-fn"}   NS (4)
  BDS 1               K~v~ 3.4                   0.4±2.05                                      NS (4)
  Correolide          K~v~ 1.x                   76.1±5.23                                     0.00696 (4)

Peak current densities for each vessel were averaged from 5 voltage steps before and after drug application, and changes expressed as a percentage.

Negative % block indicates an increase in current. NS, not significant; i.e. *P* \> 0.05.

###### 

*Pooled data showing the effects of selective Kv1α subunit inhibitors on the A-type K*^+^ *current in retinal arterioles*

  Inhibitor     K~v~ 1α Subunits Blocked   Mean Block±SEM, %                             *P* Value (No. of vessels)
  ------------- -------------------------- --------------------------------------------- ----------------------------
  Hongotoxin    K~v~ 1.1, 1.2, 1.3, 1.6    0.89±0.99                                     NS (4)
  Noxiustoxin   K~v~ 1.1, 1.2, 1.3, 1.7    −0.03±0.89[\*](#t3fn1){ref-type="table-fn"}   NS (4)
  Riluzole      K~v~ 1.4, 1.5              31.97±6.95                                    0.001045 (6)
  0K~o~         K~v~ 1.4 (not Kv1.5)       −2.04±6.05[\*](#t3fn1){ref-type="table-fn"}   NS (5)
  Flecainide    K~v~ 1.5 (not Kv1.4)       76.87±5.04                                    0.004859 (6)

0K~o~, K^+^-free.

Negative % block indicates an increase in current.
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